ClinicalTrials.gg
RecruitingNCT06725030PRECISEUpdated Nov 4, 2026

A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons

An observational study in Open Surgery, Lymphedema and Free Tissue Transfer, sponsored by MMI (Medical Microinstruments, Inc.). Recruiting at 8 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by MMI (Medical Microinstruments, Inc.) · Observational

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Nov 4, 20262 sites addedGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
455
Ages
22 Years and older
Sex
All
01

Study summary

The objective of this study is to evaluate the Symani System's safety and effectiveness for microsurgical anastomosis during free tissue transfer surgery and lymphovenous anastomosis surgery.

The primary endpoints are:

  • Effectiveness- Rate of intraoperative anastomosis patency at first attempt.
  • Safety- Freedom from device-related adverse events.

Participants will receive treatment as standard of care and be asked to:

  • Allow the researchers to access and use their information.
  • If participants are undergoing a lymphedema procedure, they will be asked to undergo a questionnaire as part of the study.
  • Participants will be asked to comply with the follow-up visits and complete all study procedures/questionnaires as outlined in the protocol.
02

Conditions studied

  • Open Surgery
  • Lymphedema
  • Free Tissue Transfer
  • Microsurgery
  • Anastomosis, Surgical

Browse trials for

03

In context

Lymphedema

529 studies on the registry are indexed under Lymphedema; 131 are open to participants now.

This study's planned enrollment of 455 is above the median of 103 across 145 observational studies indexed under Lymphedema.

Browse Lymphedema studies →

Lead sponsor

MMI (Medical Microinstruments, Inc.) is the lead sponsor of 8 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The patients selected for the PRECISE Study will be adults with a clinical indication for a microsurgical anastomosis of vessels between 0.1 and 2.5 mm in conjunction with open free flap surgery of the breast or extremities and/or lymphovenous anastomosis surgery of the extremities.

Eligibility criteria

Pre Operative Inclusion Criteria:

  1. At least 22 years of age
  2. Patient agrees to participate in the study, return for all required follow-up visits, complete all study procedures, and has willingly provided written after receiving all information related to the study, its requirements, and the robotic assisted procedure
  3. Patient has a clinical indication for a microsurgical anastomosis of vessels between 0.1 and 2.5 mm in conjunction with open free-flap surgery of the breast or extremities and/or lymphovenous anastomosis surgery of the extremities
  4. Investigator deems the candidate acceptable for free flap transfer surgery and/or lymphovenous anastomosis surgery with a robotic assisted microsurgical anastomosis in accordance with the Symani System's Instructions for Use (IFU)

Cohort Specific Pre- Operative Inclusion Criteria:

Free Tissue Transfer Surgery: N/A

Lymphovenous Anastomosis Surgery

  1. Swelling of one limb that is not completely reversed by elevation or compression
  2. Stage I-II lymphedema at screening, based on the International Society of Lymphology (ISL) staging system
  3. At least one of the following positive quantitative measurements:

    1. Volumetry differential between affected limb and contralateral limb must be at least 10% of the other
    2. Bioimpedance (L-Dex) differential, if feasible, between affected limb and contralateral limb of at least 10 units
  4. Completion of a full course of complete decongestive therapy (CDT), according to ISL guidelines, for at least 12 weeks prior to screening, including use of compression garments for at least 12 weeks without change in regimen
  5. Willingness to comply with recommended regimen of self-care, with consistent use of appropriately sized compression garments from screening through the entire study duration (through the 3-month follow-up visit).

Pre-Operative Exclusion Criteria:

  1. Patients who are incapable and/or unwilling to provide informed consent
  2. Active systemic infection under treatment with intravenous antibiotics
  3. cardiovascular, digestive, respiratory, endocrine, or central nervous system disorders, previous mental disorders, or other disorders that may significantly affect the data collection or the ability to comply with the protocol per the investigators discretion
  4. Known history of significant bleeding, coagulopathy, or Von Willebrand's disease
  5. Patients with implanted pacemaker
  6. Planned vein graft
  7. Currently receiving chemotherapy or radiation therapy
  8. History of chronic kidney disease
  9. History of chronic liver disease
  10. Currently enrolled in any other clinical studies that the investigator believes may impact patient safety or outcomes
  11. Patients belonging to vulnerable populations, such as pregnant women, or ineligible to participate for other reasons in the judgement of the investigator

Cohort Specific Pre-Operative Exclusion Criteria:

Free Tissue Transplant Surgery:

  1. Patients with buried flaps
  2. Multiple flaps planned for the procedure

Lymphovenous Anastomosis Surgery:

  1. Patients > 75 years of age
  2. Patients with prior lymphatic reconstruction surgery
  3. Patients with venous edema (arising from increased capillary filtration)
  4. Patients with other medical conditions that could lead to acute limb edema, such as (but not limited to) acute venous thrombosis or heart failure
  5. Patients with other medical conditions that could result in symptoms which overlap symptoms of lymphedema
  6. Current infection in the affected limb
  7. Patients who experience more than one episode of cellulitis in a six month period over the past two years
  8. Current evidence or a history of within the past 6 months (if the participant has undergone cancer treatment, this must have been completed > 6 months prior to enrollment)
  9. Known iodine sensitivity
  10. Patient's lymphatic disease is due to lipedema
  11. Patients with bilateral lymphedema or lymphedema in multiple anatomical locations

Intra Operative Exclusion Criteria:

  1. Any presenting condition discovered intraoperatively that, in the opinion of the investigator, would make participating in this study not in the patient's best interest
  2. The patient does not have at least one robotic stitch attempted during the index procedure
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
455 participants (estimated)
Patient registry
No

Groups and cohorts

  • Free Tissue Transfer Surgery

    Device: Symani Surgical System

  • Lymphovenous Anastomosis Surgery

    Device: Symani Surgical System

Interventions

  • DeviceSymani Surgical System

    The Symani Surgical System (Symani) is designed for open microsurgery procedures, featuring articulated and interchangeable instruments.

06

What researchers measure

Primary outcomes

  1. Freedom from device-related adverse events from the start of the index procedure through 30-days post index procedure as adjudicated by a Clinical Events Committee

    All adverse events will be evaluated from the start of the index procedure through 30-days post index procedure. Adverse events will be reviewed by a Clinical Events Committee (CEC) to determine probable or causal relationships with the device. All device-related serious adverse events will be summarized descriptively.

    Time frame: From participants index procedure through 30-days post index procedure.

  2. Intraoperative anastomosis patency at first attempt.

    Intraoperative anastomosis patency will be measured for each robotic anastomosis per standard of care and will be evaluated after the first attempt of the anastomosis during the index procedure.

    Time frame: The duration of the participants index procedure.

Secondary outcomes

  1. Intraoperative anastomosis patency prior to closure.

    Intraoperative anastomosis patency prior to closure will be measured for each robotic anastomosis per standard of care and will be evaluated prior to closure of the procedure site during the index procedure.

    Time frame: The duration of participants index procedure.

  2. Anastomosis suturing time (including robotic time and manual time).

    Anastomosis suturing time of the index procedure will be collected for each participant and summarized. Robotic anastomosis time and manual anastomosis time will be recorded for each anastomosis. For each anastomosis within an operation, the total suture time (robotic plus manual) will be derived as total robotic anastomosis time plus total manual anastomosis time.

    Time frame: The duration of participants index procedure.

  3. Number of robotic and manual stitches per anastomosis.

    The number of robotic stitches placed and the number of manual stitches placed per anastomosis in the index procedure will be collected for each anastomosis and summarized. For each anastomosis within an operation, the total stitches placed (robotic plus manual) will be derived as total robotic stitches placed plus total manual stitches.

    Time frame: The duration of participants index procedure.

  4. Procedure time.

    Procedure time of the index procedure will be collected for each participant and summarized. The incision start time and closure end time will be recorded. The procedural time will be derived from incision time subtracted from closure time.

    Time frame: The duration of participants index procedure.

  5. Technical Success.

    Technical success is defined as freedom from device malfunction resulting in unplanned conventional suturing. Device malfunctions and the associated outcome will be collected. This endpoint will be evaluated throughout the index procedure.

    Time frame: The duration of participants index procedure.

07

Study locations

8 of 8 sites recruiting
08

Updates

1 registry update since Sep 25, 2026
Sites
2 sites added
Show 2 added (2 United States)
  • Hackensack University Medical Center · Hackensack, United States
  • HCA Healthcare Trident Hospital · North Charleston, United States
Nov 4, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Yale New Haven Hospital · New Haven, United StatesContact person changed (no phone or email listed)
  • Icahn School of Medicine at Mount Sinai · New York, United StatesContact none listed→E•••@mountsinai.org
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    2 sites added
    Show 2 added (2 United States)
    • Hackensack University Medical Center · Hackensack, United States
    • HCA Healthcare Trident Hospital · North Charleston, United States
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Yale New Haven Hospital · New Haven, United StatesContact person changed (no phone or email listed)
    • Icahn School of Medicine at Mount Sinai · New York, United StatesContact none listed→E•••@mountsinai.org
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06725030
Lead sponsor
MMI (Medical Microinstruments, Inc.)
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Sep 22, 2025
Primary completion
Sep 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Clinical Operations
Contact
clinical.ops@mmimicro.com
8336646276 ext. 5
Bohdan Pomahac, MD
principal investigator · Yale New Haven Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion